Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0684249 (
lung carcinoma
)
23,830
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Synaptojanin 2 is a ubiquitously expressed polyphosphoinositide phosphatase that displays a high degree of homology in its catalytic domains with synaptojanin 1 [1,2]. Neurons of synaptojanin 1-deficient mice display an increase in clathrin-coated vesicles and delayed reentry of recycling vesicles into the fusion-competent vesicle pool, but no defects in early steps of endocytosis [3,4]. Here we show that inhibition of
synaptojanin 2
expression via small interfering (si) RNA causes a strong defect in clathrin-mediated receptor internalization in a
lung carcinoma
cell line. This inhibitory phenotype is rescued by overexpression of wild-type
synaptojanin 2
, but not of wild-type synaptojanin 1 or mutant
synaptojanin 2
that is deficient in 5'-phosphatase activity. In addition, electron-microscopic analysis shows that
synaptojanin 2
depletion causes a decrease in clathrin-coated pits and vesicles. These results suggest a role for
synaptojanin 2
in clathrin-coated pit formation and imply that lipid hydrolysis is required at an early stage of clathrin-mediated endocytosis. Taken together, our results also indicate that
synaptojanin 2
is functionally distinct from synaptojanin 1.
...
PMID:Synaptojanin 2 functions at an early step of clathrin-mediated endocytosis. 1269 22